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Abstract
In a screen for RNA mutagen resistance, we isolated a high fidelity RNA dependent RNA polymerase (RdRp) variant of
Coxsackie virus B3 (CVB3). Curiously, this variant A372V is also resistant to amiloride. We hypothesize that amiloride has a
previously undescribed mutagenic activity. Indeed, amiloride compounds increase the mutation frequencies of CVB3 and
poliovirus and high fidelity variants of both viruses are more resistant to this effect. We hypothesize that this mutagenic
activity is mediated through alterations in intracellular ions such as Mg2+ and Mn2+, which in turn increase virus mutation
frequency by affecting RdRp fidelity. Furthermore, we show that another amiloride-resistant RdRp variant, S299T, is
completely resistant to this mutagenic activity and unaffected by changes in ion concentrations. We show that RdRp
variants resist the mutagenic activity of amiloride via two different mechanisms: 1) increased fidelity that generates virus
populations presenting lower basal mutation frequencies or 2) resisting changes in divalent cation concentrations that
affect polymerase fidelity. Our results uncover a new antiviral approach based on mutagenesis.
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Introduction
Amiloride and its derivatives are potassium-sparing diuretics
used to treat hypertension and to prevent hypokalemia associated
with congestive heart failure. These compounds act by inhibiting
epithelial Na+ channels and the Na+/H+, Na+/Ca2+ and Na+/
Mg2+ antiport functions [1,2]. Due to its relatively low toxicity, the
antiviral properties of amiloride is being explored. This compound
inhibits the viroporins of coronaviruses, flaviviruses and retrovi-
ruses [3,4,5,6]. More recently, amiloride was shown to exert an
antiviral effect on rhinovirus (common cold) and Coxsackie virus
B3 (CVB3, viral myocarditis) by directly affecting virus replication
or release [7,8]. In this study, Harrison et al. isolated two viral
RNA dependent RNA polymerase (RdRp) mutants of CVB3 that
were more resistant to amiloride than wild type virus. The
mechanism for this resistance remains unclear.
We isolated one of these same CVB3RdRpmutants in a screen for
resistance to RNA mutagens with the goal of identifying higher
fidelity RdRp variants. RNA mutagens such as ribavirin, 5-
fluorouracil and 5-azacytidine are base analogs that are incorrectly
inserted into the genome by the RdRp during replication and result
in the accumulation of lethal mutations over several passages, a
process referred to as lethal mutagenesis[9,10,11,12,13]. A similar
screen previously identified a higher fidelity variant of poliovirus,
suggesting that the intrinsic fidelity of RdRps can be modulated,
despite their lack of proofreading functions [14,15]. Poliovirus RdRp
fidelity variants have since proven to be useful tools for studying the
role of genetic diversity in virus fitness and virulence, and have shown
promise in improving vaccine attenuation and genetic stability
[16,17,18]. In order to extend these observations to other medically
relevant viruses, we performed a screen for high fidelity variants of
CVB3 by selecting for resistance to the mutagenic base analogs,
ribavirin and 5-azacytidine. Here we identify a CVB3 variant with
higher fidelity that maps to a different region of the RdRp than the
previously described position 64 of poliovirus [18]. Since the same
mutation confers resistance to RNA mutagens and to amiloride, we
hypothesized that amiloride has a previously unknown mutagenic
activity. In this report we provide the first evidence for an indirect
RNA mutagenic activity for the amiloride compounds and show that
the amiloride resistant CVB3 RdRp variants resist this mutagenic
activity through two different mechanisms.
Results
Isolation of RNA mutagen resistant Coxsackie virus
(CVB3) with a high fidelity RdRp
To determine the conditions in which to generate resistance to
RNA mutagens, we treated CVB3 with various concentrations of
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ribavirin and 5-azacytidine (AZC). Mutagen concentrations above
100 mM decreased viral viability by over 90% (Figure 1A). In
order to exert a strong enough selective pressure, without
extinguishing the virus population during passage, we serially
passaged a large virus population size (106 TCID50) in 50 mM of
either mutagen. Every five passages, the viral RNA-dependent
RNA polymerase (RdRp) region was sequenced (Figure 1B). Wild
type CVB3 acquired a new CtoU mutation resulting in an Alanine
to Valine change at position 372 of the RdRp (A372V) after
passage in both ribavirin (by passage 10) and AZC (by passage 20),
that did not arise in untreated control passages. The earlier
emergence of this mutation under ribavirin treatment correlated
with ribavirin’s bias towards GtoA and CtoU transition mutations
[19], compared to AZC’s bias for CtoG and GtoC transversions
[20]. The role of A372V in resistance was confirmed by
introducing the mutation back into the CVB3 wild type cDNA
infectious clone and comparing the growth of A372V to wild type
virus treated with 3 RNA mutagens with different nucleotide
structures: ribavirin (300 mM), AZC (300 mM) and 5-fluorouracil
(FU, 150 mM). Indeed, A372V was more resistant than wild type
virus in each case (Figure 1C). A similar profile of broad resistance
to different base analogs was previously observed for the poliovirus
G64S high fidelity variant [17], suggesting that A372V is also a
higher fidelity RdRp. To confirm this with genetic data, wild type
and A372V virus stocks were prepared from infectious clones and
used to infect cells that were treated with 400 mM ribavirin, or
mock treated. At total cytopathic effect (48 hours after infection),
the mutation frequencies and distributions within each population
was determined by sequencing a 1.3 kb fragment of the capsid
region from individual genomes (Figure 1D). The untreated wild
type virus population presented a mutation frequency of 4.5
mutations per 104 nucleotides (Figure 1E and Table S1). The
A372V population, on the other hand, presented a mutation
frequency that was approximately 2-fold lower than wild type
(P=0.0225), thereby confirming the higher fidelity of this variant.
As expected, treatment with 400 mM ribavirin significantly
increased the mutation frequency of both virus populations
(P,0.0001); however, the mutation frequency of A372V remained
lower than wild type (P=0.039). Furthermore, individual clones in
the wild type virus population more often presented multiple
mutations compared to A372V (Table S1). These results further
confirmed the increased fidelity of the A372V RdRp. To provide
further evidence for the increased fidelity of A372V RdRp, an in
vitro biochemical assay was used to examine the relative levels of
misincorporation for both wild type and A372V enzymes. Briefly,
in vitro reactions were performed using equal amounts of each
purified RdRp, saturating concentrations of nucleotide and a
radiolabeled RNA primer-template substrate that permits nucle-
otide addition to be monitored by the extension of end-labeled
primer (Figure 2A) [21]. By adding GTP to the reaction, the
incorrect incorporation of this nucleotide can be monitored over
time by the accumulation of n+1 product. As observed in
Figure 2B–C, A372V RdRp consistently incorporated less GMP
over time than wild type RdRp. Interestingly, the observed rate of
correct nucleotide incorporation for wild type and A372V showed
no significant difference, whereas the observed rate of GMP
misincorporation showed a 2-fold difference between wild type
and A372V RdRp (Table 1), confirming the increased fidelity of
the A372V enzyme.
The dual resistance of A372V to RNA mutagens and to
amiloride is not a product of increased replicative
capacity
Curiously, A372V was previously isolated in a screen for
resistance to amiloride, a compound with no known mutagenic
activity, that was shown to reduce CVB3 titers by partially
inhibiting RNA synthesis [8]. Accordingly, A372V consistently
replicated to higher titers than wild type at all concentrations of
amiloride tested (Figure 3A). A possible explanation for the dual
resistance to both RNA mutagens and amiloride is that A372V
produces more RNA genomes in the presence of these compounds
and would thus titer higher than wild type. To determine whether
higher A372V titers in the presence of amiloride were due to
increased replicative capacity, one-step growth analysis was
performed, in the presence or absence of amiloride. No significant
differences in virus production kinetics were observed for wild type
and A372V grown in the absence of amiloride (Figure 3B),
indicating that increasing fidelity of the CVB3 RdRp did not
significantly impact virus multiplication. Furthermore, RNA
synthesis of wild type and A372V had similar kinetics and were
within the same order of magnitude, as determined by northern
blot analysis (Figure 3C). In fact, A372V virus produced slightly
less RNA than wild type, yet consistently titered slightly higher
because the RNA genomes made contain fewer deleterious
mutations. Importantly, differences observed for wild type and
A372V one-step growth kinetics in the presence of 400 mM
amiloride were not statistically significant, with the exception of
one time point (9 hours, p = 0.03) (Figure 3D) and northern blot
analysis revealed that both viruses were similarly inhibited in RNA
synthesis (Figure 3E). Heightened replicative capacity was thus not
responsible for the resistance of A372V to amiloride.
Amiloride compounds have a RNA mutagenic activity
Since it is unlikely that the same mutation confers resistance to
two unrelated antiviral mechanisms, we explored whether
amiloride has a previously unknown mutagenic activity. This
possibility was not evident, since amiloride is not a base analog
such as ribavirin, AZC and FU, whose mutagenic effects result
from their direct misincorporation into genomes by the error-
prone RdRp. We hypothesized that in addition to inhibiting RNA
replication, amiloride compounds increase the virus mutation
Author Summary
RNA viruses have extreme mutation frequencies, due in
large part to the erroneous nature of the viral RNA
dependent RNA polymerases (RdRp) that replicate their
genomes. Since RdRp lack proofreading and repair
mechanisms, the use of base analogs as RNA mutagens
to increase lethal mutations and extinguish the virus
population is a promising antiviral strategy. Recently, a
screen for resistance to this antiviral treatment identified a
higher fidelity RdRp variant of poliovirus, indicating that
RdRp fidelity can be modulated by single amino acid
substitutions. To extend these observations to other
viruses, we performed a similar screen using Coxsackie
virus B3 (CVB3). We identified a new high fidelity RdRp
variant which was also resistant to amiloride compounds
that have no known mutagenic activity. Using wild type
and RdRp fidelity variants of poliovirus and CVB3, we show
that amiloride compounds do have mutagenic activity and
act on RNA virus populations indirectly, by altering
intracellular ion concentrations that affect polymerase
fidelity. Our results identify a new means of targeting
viruses through increases in mutation frequency using
non-nucleoside compounds that alter the cellular environ-
ment in which the virus replicates.
Mutagenic Activity of Amiloride
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frequencies of the RNA genomes that are replicated. To address
this, wild type and A372V virus infections were performed in the
presence of either ribavirin or amiloride, or in the absence of
either compound and the mutation frequencies of the resulting
populations were determined (Figure 4A). At 400 mM amiloride,
the mutation frequency of wild type CVB3 increased from 4.5 to
Figure 1. Isolation of an RNA mutagen resistant CVB3 with a high fidelity RdRp. (A) Optimization of the RNA mutagen treatment
concentrations to select for resistant CVB3 variants. HeLa cells, treated with different concentrations of either ribavirin or AZC were infected with wild
type CVB3 at MOI of 0.01. 48 hours after infection, progeny virus was quantified by TCID50 assay. The percentage of viruses surviving treatment (y-
axis) with 50, 100, 200, 300 or 400 mM of ribavirin or AZC (x-axis) was determined by dividing the virus titers of treated populations by virus titers in
untreated controls (0 mM). Mean values 6 S.E.M are shown, N = 4, * P,0.01, ** P,0.001, ***P,0.0001. (B) Isolation of RNA mutagen resistant CVB3.
CVB3 was passaged 20 times in 50 mM ribavirin, 50 mM AZC or mock treated HeLa cells. Every 5 passages the virus population was sequenced. The
emergence of a single point mutation resulting in a A372V change in the RdRp is indicated by a solid circle. (C) A372V is resistant to three different
base analog RNA mutagens. HeLa cells treated with 300 mM of ribavirin or AZC, or 150 mM FU, were infected with either wild type CVB3 (black bars) or
A372V variant (gray bars) at an MOI of 0.01. Control infections (no drug) were also performed. At 48 hours after infection, progeny virus was titered
by TCID50 assay. Mean virus titers6 S.E.M are shown, N = 8, * P,0.05, ** P,0.01, *** P,0.001. (D) Schematic of the viral RNA genome showing the 59
untranslated region, structural capsid coding region, P2 and P3 region of non structural proteins, including the RdRp (shaded gray) and the 39
untranslated region. A 1.3 kb region of the viral capsid was RT-PCR amplified and subcloned for sequencing of individual clones to obtain the
observed mutation frequencies presented throughout this work. The total number of clones and nucleotides sequenced in each population is shown
in Table S1. (E) Average mutation frequencies of each viral population shown as the mean number of mutations per 104 nucleotides sequenced.
Statistical analysis is described in Methods. * P,0.05 statistical significance of difference between WT and A372V mutation frequencies.
doi:10.1371/journal.ppat.1001163.g001
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9.4 mutations per 104 nucleotides (P=0.0005). Similarly, A372V
virus also increased mutation frequency, from 2.5 to 6.2 mutations
per 104 nucleotides (P=0.0008). However, since the basal
mutation frequency of A372V was lower, this increase was better
tolerated, explaining the high virus titers observed (Figure 3A).
Next, we determined whether the observed mutagenic activity was
common to a wider range of amiloride compounds. Wild type
virus was treated with the amiloride derivatives EIPA, MIA and
benzamil and the mutation frequencies were determined as
described above (Figure 4B). Again, the mutation frequencies for
wild type CVB3 increased from the basal 4.5 mutations per 104
nucleotides to 8.5 for EIPA (P=0.0028) and to 9.9 for MIA
(P,0.0001). Although a tendency towards increase was observed
for benzamil (6.3 mutations per 104 nucleotides), no statistically
significant difference was established (P=0.105). Furthermore,
treatment of A372V with EIPA also increased the mutation
frequency from 2.5 to 4.1 mutations per 104 nucleotides (P=0.05)
and correlated the higher titers compared to wild type virus [8].
Figure 2. In vitro biochemical assays confirm the higher (A372V) and lower (S299T) incorporation fidelities of CVB3 variants. (A) A
radiolabeled primer/template is used to measure the incorporation of bases in vitro using purified RdRp enzymes, conditions detailed in Methods.
The templating U (in bold) permits the quantification of incorporation of the correct (ATP) or incorrect (GTP) nucleotide over time. (B) Visualization of
GTP mis-incorporation by wild type, A372V and S299T RdRp. The incorporation of GTP is monitored over time (m) as the accumulation of elongation
product (n+1) minus blank control. (C) Quantification of relative incorporation product at 2 and 5 minutes reaction time.
doi:10.1371/journal.ppat.1001163.g002
Table 1. Incorporation kinetics and relative fidelity of CVB3
RdRp variants.
Enzyme
kobs (s
21)
correct nta
kobs (s
21)
incorrect ntb
Relative
Fidelityc
wild type 8.260.5 0.00660.001 1367
A372V 7.560.5 0.00360.001 2500
S299T 7.460.2 0.00860.001 925
a1 mM ATP, determined from stopped-flow fluorescence assay for AMP
incorporation.
b5 mM GTP, determined from 32P-labeled primer-extension assay for GMP
misincorporation.
ckobs correct/kobs incorrect.
doi:10.1371/journal.ppat.1001163.t001
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Figure 3. A372V resistance to amiloride does not involve improved replication. (A) A372V is more resistant than wild type in increasing
concentrations of amiloride. HeLa cells were treated with different concentrations of amiloride and infected with wild type or A372V virus at an MOI
of 0.01. At 48 h, viable progeny virus was quantified by TCID50 assay. The mean virus titers (TCID50/ml) and S.E.M are shown, N= 3, * P,0.05. (B) One-
step growth kinetics of wild type and A372V viruses. HeLa cells were infected at MOI of 10 and the progeny virus was quantified at different hours
after infection by TCID50 assay. Mean titers (TCID50/ml) 6 S.E.M are shown, N= 3, no significant difference found. (C) The relative increase in signal
from time 0 to indicated time points is shown, values are means of 2 separate northen blots of samples from (B), error bars show range of values (D)
One-step growth kinetics of wild type and A372V viruses in the presence of 400 mM amiloride. HeLa cells were infected at MOI of 10 and the progeny
virus was quantified at different hours after infection by TCID50 assay. Mean titers (TCID50/ml) 6 S.E.M are shown, N = 3, no significant differences
found except *, p = 0.03. (E) Northern blot analysis of RNA synthesis determined 48 hours after infection with wild type or A372V virus at MOI of 0.01
in the presence or the absence of 400 mM amiloride. Two independent treatment samples per virus are shown.
doi:10.1371/journal.ppat.1001163.g003
Mutagenic Activity of Amiloride
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Figure 4. Amiloride has RNA mutagenic activity to which high fidelity RdRp variants of picornaviruses resist. (A) The mutation
frequencies of wild type and A372V viruses grown in the presence of 400 mM amiloride were determined, shown as the mean number of mutations
per 104 nucleotides sequenced. * P,0.05 statistically significant difference between WT and A372V. Asterisks in white indicate statistically significant
difference between amiloride-treated virus and the untreated parental population, *** P,0.001. (B) Mutations frequencies of wild type and A372V
viruses in the presence of other amiloride compounds. HeLa cells were treated with 40 mM of EIPA, 25 mM of MIA or 20 mM of benzamil and were
infected with wild type CVB3 virus or A372V variant (EIPA only). Statistical significance of differences in mutation frequencies are indicated. ns = not
significant, * P,0.05, ** P,0.005, **** P,0.0001. (C) Mutation profiles of wild type and A372V populations grown in the absence of drug or presence
of 400 mm ribavirin or amiloride in (A). The most commonly occurring mutations are indicated in bold. (D) Mutation frequency of wild type and G64S
polioviruses. Viral RNA genomes were extracted following infection of HeLa cells, grown in standard conditions or treated with 400 mM amiloride. A
1.0 kb region of the viral capsid was RT-PCR amplified and subcloned for sequencing of individual clones to obtain the observed mutation
frequencies (Table S1). Asterisks in white indicate statistical significance between drug treated populations and the same untreated parental virus.
* P,0.05, ** P,0.005. (E) The percentage of polioviruses surviving amiloride treatment relative to untreated control populations was determined by
plaque assay. The mean values 6 S.E.M are shown, N= 3. ** P,0.005.
doi:10.1371/journal.ppat.1001163.g004
Mutagenic Activity of Amiloride
PLoS Pathogens | www.plospathogens.org 6 October 2010 | Volume 6 | Issue 10 | e1001163
We then examined whether amiloride treatment biased the
mutation profile towards specific substitutions, as is common for
base analog RNA mutagens. In untreated populations, the
transition mutations AtoG and TtoC (UtoC on RNA genome)
were most common (Figure 4C). Treatment of populations with
ribavirin, which biases the mutation profile, resulted in the
accumulation of GtoA and CtoT (CtoU on RNA) transition
mutations. On the other hand, treatment with amiloride increased,
but did not bias, the natural mutation profile. Taken together, our
results provide the first evidence of a mutagenic activity for
amiloride compounds and suggests that A372V resists this effect by
increasing RdRp fidelity and lowering basal mutation frequency.
Another high fidelity RdRp variant (poliovirus G64S) is
also resistant to the mutagenic effect of amiloride
The G64S variant of poliovirus is another higher fidelity RdRp
variant whose fidelity altering determinant maps to a different
region of the RdRp (Figure S2). Previous studies showed that G64S
was resistant to ribavirin, AZC and FU; replicated with similar
kinetics to wild type poliovirus in one-step growth curves and
northern blot analysis; generated virus populations with lower basal
mutation frequencies and presented a higher fidelity phenotype in
biochemical incorporation assays [14,15,16,17,18]. This provided
the unique opportunity to determine whether amiloride exerts a
mutagenic activity on a different virus with a different fidelity
increasing mutation. Wild type and G64S polioviruses were treated
with amiloride, and the relative mutation frequencies were
determined (Figure 4D). The basal mutation frequency of wild
type poliovirus was 5.8 mutations per 104 nucleotides sequenced
and increased to 8.2 mutations per 104 nucleotides (P=0.039) upon
amiloride treatment. The high fidelity G64S population had a basal
mutation frequency of 4.0 mutations per 104 nucleotides that
increased to 6.7 mutations per 104 nucleotides (P=0.021) in
amiloride, but remained significantly lower than wild type virus
(P=0.05). In order to determine whether lower basal mutation
frequencies correlated with resistance, amiloride treated and
untreated populations were titrated (Figure 4E). A higher
percentage of viruses in the G64S population survived amiloride
treatment (14.3 6 2.0%) compared to the wild type poliovirus
population (1.9 6 0.9%, P=0.006). Our results therefore confirm
for two different high fidelity RdRps, that increased fidelity and
lower mutation frequency confer resistance to amiloride.
Another polymerase variant of CVB3, S299T, resists
amiloride mutagenic activity by a different mechanism
Along with A372V, Harrison et al. isolated a second RdRp variant,
S299T, in their screen for amiloride resistance [8]. By contrast, our
screens for RNAmutagen resistance failed to isolate S299T alongside
A372V. We hypothesized then that S299T is either resistant to
another amiloride-mediated antiviral effect (inhibition of RNA
synthesis, e.g.), or resistant to amiloride’s mutagenic activity by a
different mechanism. As for wild type and A372V, virus stocks were
prepared from the cDNA infectious clone of S299T virus and studies
were performed in parallel to wild type and A372V. Similar to
A372V, S299T was more resistant than wild type at all concentra-
tions of amiloride tested (Figure 5A). The one step-growth studies
performed in the absence of amiloride showed that S299T produced
virus with kinetics similar to wild type virus (Figure 5B). Likewise,
northern blot analysis of these kinetic studies revealed that S299T did
not produce higher levels of RNA in the absence of amiloride
(Figure 5C). However, although one step growth analysis of S299T
grown in the presence of amiloride also did not reveal significant
differences in virus titer compared to wild type CVB3 (Figure 5D),
northern blot analysis of RNA synthesized by 48 hours after infection
revealed that the inhibitory effects of amiloride on S299T were not as
dramatic as for wild type and A372V (Figure 5E).
Finally, to examine the potential effects of the S299T mutation
on RdRp fidelity, infections were performed in the presence of
ribavirin, amiloride, EIPA, or under mock-treatment and
mutation frequencies were determined for each population. Unlike
A372V, the mutation frequency of S299T did not suggest higher
fidelity compared to wild type (Figure 5F). Rather, it presented a
significantly higher mutation frequency (7.0 mutations per 104
nucleotides, P=0.0034), suggesting that this variant encodes a
lower fidelity polymerase. Indeed, treatment with 400 mM
ribavirin increased the mutation frequency to 28.1 mutations per
104 nucleotides (P,0.0001), significantly higher than wild type
(P=0.0207) and A372V (P,0.0001) (Figure 1E) and in accor-
dance with a lower fidelity polymerase. To confirm the lower
fidelity phenotype conferred by the S299T mutation, an in vitro
biochemical assay examining the relative levels of misincorpora-
tion with the purified S299T enzyme was performed. As shown in
Figure 2, S299T RdRp incorporated more GMP over time than
wild type RdRp, consistent with the S299T mutation decreasing
RdRp fidelity (Table 1). Unexpectedly, when treated with either
amiloride or EIPA (Figure 5F), this population did not undergo a
significant increase in mutation frequency (7.9 mutations per 104
nucleotides, P=0.442 and 7.5, P=0.859, respectively), suggesting
that S299T polymerase is completely unaffected by the mecha-
nism by which amiloride increases mutation in wild type and
A372V viruses. Hence, while A372V resists the mutagenic activity
of amiloride by increasing RdRp fidelity; S299T partially resists
RNA replication inhibition and this mutagenic effect entirely.
The mutagenic effect of amiloride is secondary to
inhibition of RNA synthesis
Our results argue that increases in mutation frequency are a
previously unknown antiviral mechanism of amiloride compounds,
but the relative contribution of RNA synthesis inhibition and RNA
mutagenesis is unclear. To examine the relative contribution of
mutagenesis to the overall antiviral effect, we determined the
mutation frequencies of wild type CVB3 virus populations treated
with increasing concentrations of ribavirin or amiloride. These data
were used to determine the fold increase in mutation frequency of
wild type virus at increasing concentrations of drug compared to
untreated control. Indeed, ribavirin treatment showed a dose-
dependent increase in mutation frequency (Figure 6A, dashed line,
right y-axis) that correlated with a decrease in virus titers (solid line,
left y-axis). These data agree with previous work showing
mutagenesis to be the principal antiviral mechanism of ribavirin in
tissue culture [10]. In contrast, treatment of CVB3 with increasing
concentrations of amiloride (at least above 100 mM) did not produce
a corresponding increase in mutation frequency (Figure 6B, dashed
line), although the decrease in virus yield was dose-dependent (solid
line). Northern blot analysis of RNA synthesis at these different
amiloride concentrations revealed a dose dependent effect on RNA
inhibition (Figure 6C). These results suggest that replication
inhibition is the principal cause of the dose-dependent drop in virus
titers and that the mutagenic effects of amiloride are the result of an
indirect, dose-independent effect on the polymerase.
Increases in intracellular ion concentrations (Mg2+, Mn2+)
may account for the mutagenic activity of amiloride
compounds
The dose dependent decrease in viral titer (Figure 6A) attributed
to inhibition of RNA synthesis is proposed to result from a direct
Mutagenic Activity of Amiloride
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Figure 5. Another polymerase variant, S299T, is resistant to both the inhibitory effect of amiloride on RNA synthesis as well as its
mutagenic activity. (A) S299T resists amiloride’s antiviral activity better than wild type virus. HeLa cells were treated with different concentrations
of amiloride and infected with wild type or S299T virus at an MOI of 0.01. At 48 hours, viable progeny virus was quantified by TCID50 assay. The mean
virus titers (TCID50/ml) and S.E.M are shown, N = 3, * P,0.05. (B) One-step growth kinetics of wild type and S299T viruses. HeLa cells were infected at
MOI of 10 and the progeny virus was quantified at different hours after infection by TCID50 assay. Mean titers (TCID50/ml)6 S.E.M are shown, N= 3, no
significant difference found. (C) The relative increase in signal from time 0 to indicated time points is shown, values are means of 2 separate northern
blots of samples from (B), error bars show range of values (D) One-step growth kinetics of wild type and S299T viruses in the presence of 400 mM
amiloride. HeLa cells were infected at MOI of 10 and the progeny virus was quantified at different hours after infection by TCID50 assay. Mean titers
(TCID50/ml)6 S.E.M are shown, N= 3, no significant differences found. (E) Northern blot analysis of RNA synthesis determined 48 hours after infection
with wild type or S299T (MOI = 0.01) virus in the presence or the absence of 400 mM amiloride. Two independent treatment samples per virus are
shown. (F) Average mutation frequencies of S299T untreated population and treated with ribavirin, amiloride or EIPA. *** P,0.0001; ns = no
statistically significant difference. NB: All data from Figure 5 was obtained simultaneously with that for Figure 3 and separated for clarity of
presentation, hence, wild type and A372V data is the same for both figures, except for (C).
doi:10.1371/journal.ppat.1001163.g005
Mutagenic Activity of Amiloride
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interaction of amiloride with the RdRp [8]. Given that dose
dependence of mutation frequency was not observed for amiloride,
we hypothesized that this mutagenic effect was the indirect result
of the effect of amiloride on the cellular environment. Indeed,
previous studies have shown amiloride treatment to alter the
intracellular concentrations of free Na+, Ca2+, Mg2+, which in turn
Figure 6. The mutagenic activity of amiloride is an indirect, secondary antiviral effect that correlates with increases in intracellular
divalent cation (Mg2+ or Mn2+) concentrations. (A) Dose dependence of virus titer decrease and mutation frequency increase with ribavirin
treatment. The reduction in wild type virus yield (solid lines, left y axis) is shown as a function of the percentage of viruses surviving treatment with
different concentrations of ribavirin. The increase in mutation frequency (dashed lines, right y-axis) of the starting population at these same drug
concentrations is shown. (B) Dose dependence of amiloride treatment, as in (A). (C) Inhibition of RNA synthesis by amiloride is dose dependent.
Northern blot analysis of RNA synthesis of wild type virus treated with different concentrations of amiloride. Cells were infected at MOI of 0.01 and
RNA was extracted 48 hours after infection. (D–F) Treatment with Mg2+ and Mn2+, but not Na+ or Ca2+, increase the mutation frequency of wild type
(D) and A372V (E), but not S299T (F). Cells were infected at MOI of 0.01 with virus in media supplemented with the indicated concentrations of salts
and mutation frequencies were determined in progeny populations 48 hours after infection. * P,0.05, ** P,0.01, *** P,0.0001; ns = no statistically
significant difference. (G) Passage of wild type virus in high concentrations of Mg2+ and Mn2+ selects for high fidelity A372V. Virus was passaged 20
times in 5 mM MgCl2, 1 mM MnCl2 or regular media. At the indicated passage numbers the virus population was sequenced. The emergence of a
single point mutation resulting in a A372V change is indicated by a solid circle.
doi:10.1371/journal.ppat.1001163.g006
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can alter the equilibrium levels of other ions, including Mn2+
[1,2,22]. Mg2+ and Mn2+ are interesting candidates since they are
cofactors essential for incorporation activity of polymerases such as
viral RdRp. In our own cell culture conditions, we confirmed that
in addition to the more commonly studied effects on Na+, Mg2+
levels are also significantly perturbed in cells treated with amiloride
(P=0.0009) (Figure S1).
To examine the potential role of altered intracellular cation
concentrations in the observed mutagenic activity, wild type,
A372V and S299T viruses were grown in cell media supplemented
with high concentrations of either NaCl, CaCl2, MgCl2 or MnCl2
and the resulting mutation frequencies were determined. Growth
of all three viruses in either NaCl or CaCl2 had no significant
effect on mutation frequency (Figure 6D–F). Increasing intracel-
lular Mg2+ or Mn2+ concentrations on the other hand, resulted in
a significant increase in mutation frequency for both wild type
(P,0.0001 for Mg2+, P=0.046 for Mn2+, Figure 6D) and A372V
(P=0.021 for Mg2+, P=0.0073 for Mn2+, Figure 6E) viruses, the
frequencies of A372V being significantly lower than those of wild
type (P,0.0001) as would be expected of the higher fidelity
variant. In contrast, the mutation frequency of S299T remained
unchanged (P=0.695 for Mg2+, P=0.769 for Mn2+, Figure 6F).
Importantly, one-step growth analysis of each virus grown in the
presence of this concentration of MgCl2 confirmed that replication
itself was not affected (Figure S3). Given the similar sensitivity and
resistance profiles of each variant in both these and the amiloride
treated populations, our results support the notion that amiloride
induced mutagenesis results from changes in intracellular
concentrations of the essential divalent cation cofactors. To gather
further support for the link between amiloride mutagenesis and
Mg2+/Mn2+ concentrations, wild type virus was serially passaged
in the presence of either compound and the RdRp regions of the
passaged virus populations were sequenced at the intervals
indicated (Figure 6G). Interestingly, wild type virus that was
grown in the presence of MnCl2 had acquired (passage 5) and
fixed (passage 7 onward) the same high fidelity A372V mutation
that was selected by RNA mutagen (Figure 1) and amiloride [8]
passage. Similarly, passage of wild type virus in MgCl2 selected the
same high fidelity which was fixed in the population by passage 15.
Discussion
In this report, we identify a previously undescribed mutagenic
effect of amiloride treatment on CVB3 and poliovirus (Figure 4)
and confirm that amiloride inhibits RNA synthesis of Coxsackie
B3 virus (Figure 3E, 5E). What are the relative contributions of the
two activities to the observed antiviral effect of amiloride
compounds? The dose dependent inhibition of RNA synthesis
(Figure 6C) that correlates with the dose dependent reduction in
wild type virus titers (Figure 6B) suggests that this is the principal
antiviral activity for amiloride. This may reflect a direct interaction
of amiloride with the RdRp, perhaps through blocking of the
nucleotide entry tunnel or catalytic site, as was suggested by
Harrison et al [8]. More detailed in vitro biochemical or in vitro
replication assays should help determine the nature of this
interaction.
What is the molecular basis for amiloride induced mutagenesis?
The lack of dose dependence of the observed mutagenic effect at
higher concentrations of amiloride (Figure 6B) that is typically
observed for RNA mutagens such as ribavirin (Figure 6A) led us to
seek an indirect mechanism for amiloride induced mutagenesis.
Amiloride inhibits epithelial Na+ channels, Na+/H+ ion anti-
porters and other less characterized ion exchangers (Na+/Ca2+
and Na+/Mg2+) which could in turn affect the equilibrium of other
ions, such as Mn2+ [2,22]. Indeed, in our own experimental
conditions we observed a significant alteration of intracellular
Mg2+ concentrations, although 800 mM amiloride treatment was
necessary because of detection limits (Figure S1). Since Mg2+ and
Mn2+ are essential cofactors for polymerase activity and nucleotide
insertion [23], we explored a potential link between amiloride
treatment, Mg2+/Mn2+ levels and CVB3 mutation frequency.
Indeed, we found that increases in intracellular Mg2+ and Mn2+
correlate with increased virus mutation frequency (Figure 6D–E).
Whether amiloride inhibits Mg2+ and/or Mn2+ transporters
directly (which have not yet been identified in eukaryotes) or
indirectly through effects on Na+ channels and exchangers will be
difficult to determine. Studies with other channel blockers of
different structure may help to pinpoint this mechanism, although
redundancy between channels may mask their effect. Nevertheless,
the mutagenesis and resistance profiles of the A372V and S299T
amiloride-resistant variants support this link between cation
concentrations and amiloride’s mutagenic effect.
A372V is a higher fidelity RdRp variant that generates virus
populations with lower basal mutation frequencies than wild type
populations. In result, this virus population, although not
impervious to the effects of mutagens, can better tolerate a
moderate increase in mutation frequency that would otherwise
lethally mutagenize the wild type population. Accordingly, A372V
mutation frequencies increased following ribavirin treatment,
amiloride treatment and treatment with high concentrations of
Mg2+ and Mn2+ but in all cases, the frequencies were significantly
lower than wild type populations under the same treatments.
Unlike S299T, this variant is solely resistant to the mutagenic
antiviral activity since its RNA synthesis is as inhibited by
amiloride as wild type virus (Figure 3E). It is perhaps for this
reason that passage of wild type virus in Mg2+ and Mn2+ (that
mimics only the mutagenic, and not the RdRp inhibitory, activity
of amiloride), resulted in the selection of the high fidelity A372V
variant over S299T (Figure 6G).
The S299T variant seems to resist amiloride on both fronts:
RNA synthesis is less inhibited (Figure 5E) and its mutation
frequency is unchanged (Figure 5F). Whether S299T’s dual
mechanisms of resistance to both of amiloride’s antiviral activities
are tightly coupled, or coincidental, remains to be determined.
Nevertheless, a similar lack of mutagenic effect by Mg2+ and Mn2+
treatment (Figure 6F) provides further support for the role of
divalent cations in amiloride-induced mutagenesis. However, this
seems to come at the cost of decreasing overall RdRp fidelity, as
evidenced by its hypersensitivity to the nucleoside mutagen
ribavirin and in vitro biochemical data (Figure 2 and 5F).
Interestingly, low fidelity variants of poliovirus and FMDV also
map to the same b9–a11 loop, a domain interacting with the
active site where coordination of one of two divalent cation
cofactors and the incoming nucleotide occurs [24,25]. Alterations
to this domain may alter RdRp dependence on the relative
availability of the Mg2+ cofactor, thereby resulting in a lower
fidelity, Mg2+ concentration-insensitive RdRp or may change its
preference for Mg2+ to Mn2+. In poliovirus, a position 297 variant
was shown to be a lower fidelity RdRp in vitro and a position 296
variant of FMDV also presented higher mutation frequencies
[24,26]. In earlier studies, position 297 poliovirus variants were
found to be dependent on Mn2+ for growth[27]. Biochemical
assays have shown that poliovirus RdRp activity in the presence of
Mn2+ results in higher mutation frequencies[28,29] and if S299T
is Mn2+ dependent, it may explain the higher basal mutation
frequency relative to wild type virus.
The use of RNA mutagens to extinguish viral popula-
tions by hypermutation is a promising antiviral approach
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[11,12,13,19,30,31,32]. Lower fidelity variants (such as S299T)
could more readily identify weakly mutagenic base analogs that
could later be improved, while higher fidelity variants (such as
A372V) would help test the efficacy of the strongest of mutagens,
of nucleoside or non-nucleoside structure [33,34,35]. Since the
description of lethal mutagenesis using base analogs, there is
speculation as to whether other compounds can alter mutation
frequency through direct or indirect action on the RdRp. It is
important to note that the mutagenic activity of amiloride
observed in our study was not as significant as that observed for
nucleoside RNA mutagens. This raises a two-sided question: is the
activity of amiloride strong enough to lethally mutagenize the virus
population over a prolonged exposure or would the moderate
increase in mutation frequency help the virus more rapidly evolve
or escape immune responses? Under these experimental condi-
tions, the mutagenic effect was strong enough to force the virus to
develop two mechanisms of resistance, suggesting that this
mutagenic activity alone was sufficiently detrimental to the virus.
Whether the antiviral mutagenic effect we observed here occurs at
physiological intracellular amiloride concentrations in humans is
not yet known and how this may affect the fidelity of cellular RNA
polymerases remains to be studied. Nevertheless, our work
uncovers a new target for drug discovery - compounds that
induce reversible alterations of the intracellular concentrations of
essential cation cofactors for viral RdRp. Our results should
encourage screening of compound libraries for new molecules
that, through direct interaction with RdRps or indirect effects on
the intracellular environment, may alter the mutation frequency of
RNA viruses by modulating polymerase fidelity.
Finally, our study identifies two new CVB3 RdRp fidelity
variants. To date, only position 64 variants of poliovirus were
shown to exhibit increased RdRp fidelity [15,18]. Despite having
similar RdRp structures [36,37,38], A372V maps to a distant
region of the polymerase (Figure S2). Our previous work and
current findings (higher fidelity A372V and lower fidelity S299T),
along with the description of lower fidelity RdRp of poliovirus and
Foot and Mouth Disease virus [24,26], suggest that the intrinsic
fidelity of RdRps is defined by multiple residues. The full extent of
this fidelity network and whether it translates across RdRps from
different virus families is yet to be determined. In addition to their
utility in studies such as our current report, RdRp variants are
valuable tools to study viral evolution and adaptation of RNA virus
populations in vivo [14,16,17]. It will be interesting to determine
how a virus population of increased or decreased genetic diversity
will behave in the context of Coxsackie virus infection.
Methods
Cells, plasmids, drugs
HeLa (Young) and Vero cells were maintained in DMEM
medium with 10% newborn calf serum. Plasmid bearing the cDNA
of Coxsackie virus B3 (Nancy) strain was a kind gift of F. van
Kuppeveld (Radboud University, Nijmegen, Netherlands). Plasmids
containing poliovirus cDNAs were previously described [17]. The
following compounds were obtained from Sigma Aldrich:
Ribavirin IUPAC 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxy-
methyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide);
5-fluorouracil IUPAC 5-fluoro-1H-pyrimidine-2,4-dione;
5-Azacitidine IUPAC 4-amino-1-b-D-ribofuranosyl-1,3,5-tria-
zin-2(1H)-one;
Amiloride IUPAC 3,5-diamino-6-chloro-N-(diaminomethylene)
pyrazine-2-carboxamide;
EIPA IUPAC 3-amino-6-chloro-N-(diaminomethylidene)-5-
[ethyl(propan-2-yl) amino]pyrazine-2-carboxamide;
MIA IUPAC 3-amino-5-[tert-butyl(methyl)amino]-6-chloro-N-
(diaminomethylidene)pyrazine-2-carboxamide;
benzamil IUPAC 3,5-diamino-N-(N’-benzylcarbamimidoyl)-6-
chloropyrazine-2-carboxamide.
Generation of virus stocks by in vitro transcription and
electroporation
All studies were performed on virus stocks (wild type, A372V or
S299T) generated from cDNA infectious clones. The A372V and
S299T variants were constructed using the Quikchange XL site
directed mutagenesis kit (Stratagene) and the CVB3-Nancy
infectious cDNA. Three infectious cDNA clones of each variant
(A372V and S299T) were obtained, sequenced and used to
generate three independent virus stocks. Three virus stocks of wild
type virus were also prepared in this manner. Each of three stocks
served as one of three triplicate samples in replication studies, and
RNA mutagen and amiloride compound sensitivity assays. For
mutation frequency data, the virus population generated by clone
1 for each variant was used throughout the study. Basal mutation
frequencies were determined on 2 independently generated
samples of each variant and no statistically significant differences
in mutation frequencies were found. CVB3 cDNA plasmids were
linearized with Sal I and poliovirus cDNA plasmids, with Eco RI.
Linearized plasmids were purified with the Qiagen PCR
purification kit. 2.5 mg of linearized plasmid was in vitro transcribed
using T7 RNA polymerase (Fermentas). 8 mg of transcript was
electroporated into 46106 Vero cells that were washed twice in
PBS (w/o Ca2+ and Mg2+) and resuspended in PBS (w/o Ca and
Mg) at 107 cells/ml. Electroporation conditions were as follows:
0.4 mm cuvette, 25 mF, 700 V, maximum resistance, exponential
decay in a Biorad GenePulser XCell electroporator. Cells were
recovered in DMEM. 500 ml of p0 virus stock was used to infect
36106 Vero cells in T25 flasks, to produce p1 virus. 250 ml of p1
virus was used to infect 16107 Vero cells in DMEM-10% NCS in
T75 flasks, to produce p2 virus. For each passage, virus was
harvested at total cytopathic effect (CPE) by one freeze-thaw cycle
and clarified by spinning at 10 K rpm for 10 minutes.
Determination of viral titers: By TCID50
Ten-fold serial dilutions of virus were prepared in 96-well
round-bottom plates in PBS. Dilutions were performed in
octuplate and 100 ml of dilution were transferred to 104 Vero
cells plated in 100 ml of DMEM. After 5 days living cell
monolayers were colored by crystal violet. TCID50 values were
determined by the Reed and Muensch method. By plaque
assay. HeLa cells were seeded into 6-well plates and virus
preparations were serially diluted (10-fold) in PBS. Cells were
washed twice with PBS and infected with 250 ml of dilution for 30
minutes at 37uC, after which a semisolid overlay comprised of
DMEM medium and 1.2% w/v Avicell (FMC Biopolymer) was
added. 2 days after infection, cells were washed and stained with
crystal violet 0.2%, and plaques were enumerated.
Isolation of RNA mutagen and divalent cation resistant
viruses
HeLa cell monolayers were pretreated with 50 mM ribavirin,
50 mM 5-Azacytidine, 5 mM MgCl2 or 1 mM MnCl2 for 2 hours,
then infected with 106 TCID50 of CVB3. Blind serial passages
were then performed on fresh mutagen-treated HeLa cell
monolayers (250 ml of virus-containing supernatant). At the
indicated passage intervals, viral RNA was extracted from purified
virions with Trizol reagent (Invitrogen) and RT-PCR was
performed (Titan One-Step, Roche). PCR products were
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sequenced to identify consensus sequence changes within the
RdRp region, between nucleotides 4701 and 7903.
RNA mutagen, amiloride compound and cation assays
HeLa cell monolayers in 6-well plates were pretreated for
2 hours (ribavirin, AZC, FU, NaCl, CaCl, MgCl2, or MnCl2) or
10 hours (amiloride compounds) with different concentrations of
compound as indicated. We chose and verified concentrations of
compounds that were not toxic to cells over a 72 hours period. For
amiloride compounds, we chose and confirmed concentrations
corresponding to virus inhibitory concentration (IC50) values that
were not toxic to cells, as determined by Harrison et al.[8]. Cells
were then infected at an MOI=0.01 with passage 2 virus.
48 hours post-infection, virus was harvested by one freeze-thaw
cycle and virus titers (TCID50 or plaque assay) were determined.
Replication kinetics
For replication studies, HeLa cells were either pretreated with
400 mMamiloride or mock treated and infected at anMOI of 10. For
one-step growth kinetics, transfected cells were frozen at different
time points after infection and later titered by TCID50 assay. For
Northern blot analysis, total RNA from infected cells was extracted
by Trizol reagent (Invitrogen) and purified. 5 mg of total RNA were
used per sample (measured by Nanodrop). Gels were transferred onto
a nitrocellulose membrane (Whatman Turboblotter SuperCharge
Nylon membrane kit), hybridized overnight with a dCTP-a32P
labeled DNA probe corresponding to 200 bp of the RdRp, visualized
on a Storm Phosphorimager and analyzed by ImageQuant.
Determination of mutation frequency by sequencing
At total CPE, viral RNA in supernatants was extracted and RT-
PCR amplified using the primers sets 878Forward and 2141Rev
for CVB3 virus and 1337For and 2651Rev for poliovirus. The
resulting PCR products were purified on column (Nucleospin,
Macherey-Nagel) and TopoTA cloned (Invitrogen). Blue/white
screening was used on single colony transformants, positive clones
were sequenced (GATC Biotech). Sequence data was analyzed
using the Lasergene software package (DNAStar Inc). For
statistical purposes, we retained sequence data only over the
region for which every clone was represented (859 nucleotides for
CVB3 and 884 nucleotides for PV). The number of mutations per
104 nucleotides sequenced was determined using the total
mutations identified per population over the total number of
nucleotides sequenced for that population multiplied by 104. For
each population, between 68 and 178 clones were sequenced
representing between 58,000 to 153,000 nucleotides per sample
(see Table S1). If the same mutation recurred in the same
population, this was only counted once; however, this only
occurred in two instances of one single repetition each and was not
sufficient to change the mutation frequency values and statistics.
Cytosolic Mg2+ measurements in HeLa cells following
amiloride treatment
A confluent layer of HeLa cells was treated with 800 mM
amiloride for 10 hours and incubated with PBS containing 100 mM
Ethylene glycol-bis (b-aminoethyl ether)-N,N,N’,N’-tetraacetic acid
(EGTA) for 15 min, to chelate Ca2+, before lysis in H2O-Tween
0.1%. The ratiometric magnesium indicator mag-fura-2 (Invitro-
gen) was added to a final concentration of 2 mM to 1 ml of sample
and fluorescence was measured at 25uC using a Quanta-Master
QM4CW spectrofluorometer (PTI) using a 1 cm path length quartz
cuvette thermostated at 25uC. Excitation scans were performed
from 250 to 490 nm with 1 nm steps, using 1 nm bandwidth;
emission was monitored at 530 nm with 5 nm bandwidth.
Continuous recordings of fluorescent intensities at 330 nm and
370 nm were transformed into 330/370 wavelength ratios.
Statistical analyses
For one step growth curves, mutagen treatment assays and
Mg2+concentration assays, the two-tailed paired student’s t tests
were used to determine significance with 95% confidence
intervals. For mutation frequencies, x2 tests and two-tailed Mann
Whitney U tests were performed. x2 tests compared the total
number of mutations in a population to total nucleotides
sequenced. Mann Whitney tests compared the ranked scores of
number of mutations found in individual clones grouped by
population. In all cases, Mann Whitney tests gave the more
conservative P values and are the indicated here. Statistics were
performed using Prism software (GraphPad Inc).
In vitro biochemical assay for measuring RdRp fidelity
All RNA oligonucleotides were from Dharmacon Research,
Inc.; [c-32P]-ATP (7000 Ci/mmol) was from MP Biomedical; T4
polynucleotide kinase was from USB; ATP and GTP were from
GE Healthcare; all other reagents were of the highest grade
available from Sigma, Fisher or VWR. RNA oligonucleotides were
purified by denaturing PAGE and end-labeled by using
[c-32P]ATP and T4 polynucleotide kinase as described previous-
ly[21]. Concentrations were determined by measuring the
absorbance at 260 nm using a Nanodrop spectrophotometer and
using the appropriate calculated extinction coefficient.
Construction, expression and purification of wild type,
A372V and S299T CVB3 RdRp
Expression constructs for wild type, A372V and S299T CVB3
RdRp were created by using standard recombinant DNA protocols.
DNA sequences were amplified using the appropriate CVB3 cDNA
as template. Forward and reverse primers employed for amplifica-
tion were selected based on the presence of unique restriction sites
suitable for cloning of the 3D gene (RdRp) into the pSUMO
expression plasmid[39] E. coli Rosetta cells were tansformed with
the appropriate plasmid and these cells were used to produce an
inoculum for large-scale growth. CVB3 3D gene expression was
induced during exponential growth by addition of isopropyl-b-D-
thiogalactopyranoside or by using auto-induction[40]. Induced cells
were lysed in appropriate buffers, and the enzymes were purified to
apparent homogeneity by using standard column chromatography
resins and protocols[39].
In vitro nucleotide incorporation assays
Reactions were performed at 30uC. 32P-labeled primer
extension assays: 2 mM CVB3 RdRp was mixed with 0.5 mM
[32P]-primer-template substrate in 50 mM HEPES pH 7.5, 5 mM
MgCl2, 60 mM ZnCl2 and 10 mM 2-mercaptoethanol. Reactions
were initiated by the addition of ATP or GTP (1 or 5 mM) in
50 mM HEPES pH 7.5, 5 mM MgCl2, 60 mM ZnCl2, 10 mM 2-
mercaptoethanol and 200 mM NaCl. Reactions were quenched at
various times by addition of quench buffer (50 mM EDTA, 70%
formamide, 0.025% bromphenol blue, and 0.025% xylene
cyanol). CVB3 RdRp was diluted immediately prior to use in
50 mM HEPES pH 7.5, 20% glycerol and 10 mM 2-mercapto-
ethanol. The volume of enzyme added to any reaction was always
less than or equal to one-tenth the total volume. Products were
resolved by denaturing PAGE. Stopped-flow fluorescence assay:
Pre-steady state stopped-flow fluorescence experiments were
performed using a Model SF-2001 stopped-flow apparatus (Kintek
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Corp., Austin, TX) equipped with a waterbath. All reactions were
performed at 30uC. 2 mM CVB3 3Dpol was mixed with 0.5 mM
primer-template substrate containing 2-aminopurine ribonucleo-
side on the 59 side of the templating base[41] in 50 mM HEPES
pH 7.5, 5 mM MgCl2, 60 mM ZnCl2 and 10 mM 2-mercapto-
ethanol. Reactions were initiated by the addition of 1 mM ATP in
50 mM HEPES pH 7.5, 5 mM MgCl2, 60 mM ZnCl2, 10 mM 2-
mercaptoethanol and 200 mM NaCl. After mixing, reactant
concentrations were reduced by 50%. Fluorescence emission was
monitored by using a 370 nm cut-on filter (model E370LP,
Chroma technology corp., Rockingham, VT.). The excitation
wavelength used was 313 nm. For each experiment, at least four
fluorescence traces were averaged. The relative fluorescence was
plotted as a function of time and fit to a single exponential
equation, F~A|e {kobs| tð ÞzC, where F is the relative
fluorescence intensity, kobs is the observed rate constant for
nucleotide incorporation, t is the time and C is an offset.
Product analysis, denaturing PAGE
Quenched reaction mixtures were heated to 70uC for 2–5 min
prior to loading 5 ml on a 20% denaturing polyacrylamide gel
containing 1X TBE and 7 M urea. Electrophoresis was performed
in 1X TBE at 85 watts. Gels were visualized by using a
PhosphorImager and quantified by using the ImageQuant
software (Molecular Dynamics). Data were fit by nonlinear
regression using the program, KaleidaGraph (Synergy Software,
Reading, PA).
Supporting Information
Figure S1 Amiloride treatment of cells increases free intracel-
lular Mg2+ concentrations. HeLa cells were treated for 10 hours
with 800 mM or without amiloride, washed, and lysed. Increases in
intracellular Mg2+ concentrations were determined by the change
in the ratio of emission signals at 330/370 nm using mag-fura-2
indicator. The mean values and S.E.M. are shown. * P=,0.05,
N= 6.
Found at: doi:10.1371/journal.ppat.1001163.s001 (0.39 MB EPS)
Figure S2 Localization of fidelity altering mutations in picorna-
virus RdRp. The crystal structure of the CVB3 RdRp [36,37] is
shown, in color format progressing from N terminus (blue) to C
terminus (red). The position 64 shown to increase the fidelity of
poliovirus RdRp, position 299 that decreases fidelity of CVB3
RdRp and position that increases fidelity of CVB3 RdRp are
indicated and illustrated in ball structure. The location of the
catalytic site of the picornavirus RdRp is also indicated and
represented in line structure.
Found at: doi:10.1371/journal.ppat.1001163.s002 (3.00 MB EPS)
Figure S3 Replication of wild type, A372V and S299T is not
affected by increasing the concentration of MgCl2 in the media.
One-step growth kinetics of wild type A372V and S299T viruses
were performed in the presence of 5 mM MgCl2. HeLa cells were
infected at MOI of 10 and the progeny virus was quantified at
different hours after infection by TCID50 assay. Mean titers
(TCID50/ml) 6 S.E.M are shown, N= 3, no significant difference
found.
Found at: doi:10.1371/journal.ppat.1001163.s003 (0.50 MB EPS)
Table S1 Mutation distribution data for experiments presented.
Found at: doi:10.1371/journal.ppat.1001163.s004 (0.08 MB PDF)
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